Merck Arcoxia/Cardiome Oxyprim for gout
Executive Summary
FDA's Arthritis Advisory Committee will discuss NDAs for Merck's Arcoxia for acute gout and Cardiome's Oxyprim in the treatment of gout at its June 2-3 meeting. On June 2, the committee will consider Oxyprim and trial design/endpoints for chronic gout. Arcoxia will be discussed on June 3 in conjunction with trial endpoints and design for acute gout. The topic was previously scheduled for discussion on Nov. 13, 2003, but the meeting was postponed. The meeting will be held at CDER's advisory committee conference room at 5630 Fishers Lane in Rockville, Md. at 8 a.m...